Philadelphia, PA (August 19, 2019) – Oncoceutics, Inc., announced that it has signed an exclusive, world-wide license for US patent #10,239,877, entitled “Pharmacophore for trail induction”, from The Scripps Research Institute (“Scripps”), covering the composition of matter of ONC201 as well as other molecules in the imipridone family. This patent has been issued in the
Philadelphia, PA (July 30, 2019) – Oncoceutics, Inc. announced that a series of presentations at the 2019 DIPG/DMG Symposium to be held August 2-3 in Sydney, Australia, will highlight ONC201 as a promising treatment for specific types of lethal brain cancer. These presentations are part of a session describing progress in new drug development for
Philadelphia, PA (July 23, 2019) – Oncoceutics, Inc., announced a collaboration with the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Consortium (PPTC) to enable tumor type selection for ONC201 clinical trials in pediatric oncology beyond diffuse midline gliomas. The PPTC program addresses key challenges associated with the development of new therapies for children with
Philadelphia, PA (July 17, 2019) – Oncoceutics, Inc. issues this announcement on Glioblastoma Awareness Day to reiterate its support for all those suffering from, or broadly affected by, gliomas. A bipartisan resolution, Senate Resolution 245, introduced on May 16, 2019, by U.S. Senator Lindsey Graham (R-SC), with the support of Senators Mitch McConnell (R-KY), Elizabeth
Business Development